Oregon Prescription Drug Affordability Board

Oregon Prescription Drug Affordability Board Regular Meeting

Wednesday, January 21, 2026
Minutes approved by the board on February 18, 2026

Web link to the meeting video: https://youtu.be/cbykiLL17YE
Web link to the meeting materials: https://dfr.oregon.gov/pdab/Documents/20260121-PDAB-document-package.pdf

Call to order: Chair Shelley Bailey called the meeting to order at 8:03 a.m.
Roll call:
Present: Chair Shelley Bailey, Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, and John Murray
Absent: None

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: John Murray provided a statement. View at video minute 00:00:53.

Approval of board minutes: Chair Bailey approved by consensus the Dec. 17, 2025, minutes as shown on Pages 2-3 of the agenda materials. View at video minute 00:01:47.

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View the video at minute 00:02:12.

General public comment: The board received public comment from the following individuals who signed up in advance: Dharia McGrew, PhRMA; and Ranier Simons, Community Access National Network. The board received 10 written comments, which are posted on the PDAB website. View at video minute 00:10:30.

2025 drug review: Votes to identify up to nine prescription drugs and at least one insulin product that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in Oregon, pursuant to ORS 646A.694: See the scoring rubric on Pages 5-7 of the agenda materials. Board members voted on each of the 23 prescription drugs on the final 2025 subset list. They identified four prescription drugs that may create affordability challenges (three other drugs and one insulin product): Vraylar; Cosentyx; Trulicity; and Lantus SoloStar. See vote count below. See Table 1 on Page 9 of these minutes for the final prescription drug list for Oregon PDAB 2025 review. View the votes at video minute 00:15:22.

MOTION to identify Vraylar as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
No: Chris Laman
MOTION PASSED 6-1

MOTION to identify Entresto as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Dan Kennedy
No: Lauri Hoagland, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 1-6

MOTION to identify Ajovy as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Lauri Hoagland
Yes: None
No: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 0-7

MOTION to identify Emgality as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Dan Kennedy, John Murray
No: Lauri Hoagland, Michele Koder, Chris Laman, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 2-5

MOTION to identify Nurtec ODT as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:

Motion: Dan Kennedy
Second: Michele Koder
Yes: Dan Kennedy, John Murray, Vice Chair Dan Hartung
No: Lauri Hoagland, Michele Koder, Chris Laman, Chair Shelley Bailey
MOTION FAILED 3-4

MOTION to identify Ubrelvy as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Lauri Hoagland, Dan Kennedy, Michele Koder
No: Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 3-4

MOTION to identify Trelegy Ellipta as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: John Murray
Yes: None
No: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 0-7

MOTION to identify Eliquis as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Lauri Hoagland
Yes: Dan Kennedy
No: Lauri Hoagland, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 1-6

MOTION to identify Xarelto as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Dan Kennedy

No: Lauri Hoagland, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 1-6

MOTION to identify Cosentyx as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: John Murray
Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
No: None
MOTION PASSED 7-0

MOTION to identify Creon as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: John Murray
Yes: Lauri Hoagland, Michele Koder, John Murray
No: Dan Kennedy, Chris Laman, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 3-4

MOTION to identify Jardiance as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Lauri Hoagland
Yes: None
No: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 0-7

MOTION to identify Mounjaro as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Dan Kennedy
No: Lauri Hoagland, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 1-6

MOTION to identify Ozempic as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: None
No: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 0-7

MOTION to identify Rybelsus as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Dan Kennedy
No: Lauri Hoagland, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 1-6

MOTION to identify Trulicity as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
No: None
MOTION PASSED 7-0

MOTION to identify Basaglar KwikPen as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: None
No: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 0-7

MOTION to identify Insulin Glargine-yfgn as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: None
No: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 0-7

MOTION to identify Lantus as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Dan Kennedy
No: Lauri Hoagland, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 1-6

MOTION to identify Lantus SoloStar as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Dan Kennedy
No: Lauri Hoagland, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 1-6

Note: The board voted twice on motions for Lantus SoloStar. The motion failed in the first vote. After the board's additional discussion, the motion passed in the second vote. The second vote count is recorded below.

MOTION to identify Semglee as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: None

No: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 0-7

MOTION to identify Toujeo Max SoloStar as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: Michele Koder
Yes: Chair Shelley Bailey
No: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung
MOTION FAILED 1-6

MOTION to identify Toujeo SoloStar as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Dan Kennedy
Second: John Murray
Yes: Dan Kennedy, John Murray
No: Lauri Hoagland, Michele Koder, Chris Laman, Vice Chair Dan Hartung, Chair Shelley Bailey
MOTION FAILED 2-5
Note: Chair Bailey clarified later in the meeting that she intended to vote no on Toujeo SoloStar.

After additional discussion, the board voted a second time on Lantus SoloStar and the motion passed.

MOTION to identify Lantus SoloStar as a drug that may create affordability challenges for the health care systems or high out-of-pocket costs for patients in this state, pursuant to ORS 646A.694.
Board Vote:
Motion: Lauri Hoagland
Second: Michele Koder
Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Vice Chair Dan Hartung, Chair Shelley Bailey
No: None
MOTION PASSED 7-0

Recommendations to include in the 2025 drug review report: The board discussed recommendations as shown on Pages 8-11 of the agenda materials. The report will go to the Oregon Legislature in March. View the discussion at video minute 00:54:33.

Executive session for legal advice pursuant to ORS 192.660(2)(f): The board adjourned to executive session for legal advice pursuant to ORS 192.660(2)(f). No decisions were made in executive session.

Return to open session: The board returned to open session and took a five-minute break as listed on the agenda. The board returned from break, took a roll call, and determined the board met quorum.

2026 drug review: Discussion and review of the prescription drugs and insulin products preliminary lists: The board continued discussion about the preliminary lists of prescription drugs and insulin products for the 2026 drug reviews, based on commercial insurer reporting from calendar year 2024. The **preliminary lists** of drugs are posted on the PDAB website. View at video minute **01:44:00**.

Announcements: Chair Bailey announced the next board meeting will be Feb. 18, 2026, at 8 a.m. View at video minute **03:01:36**.

Adjournment: Chair Bailey adjourned the meeting at 11:44 a.m. with all board members in agreement. View at video minute **03:01:45**.

Oregon Prescription Drug Affordability Board

Table 1: Final prescription drug list for Oregon PDAB 2025 review

On Jan. 21, 2026, the board identified the drugs marked '**Yes'** in Table 1 as drugs that may create affordability challenges for the health care systems or patient out-of-pocket costs pursuant to ORS 646A.694.

Review grouping number	Therapy class	Drug name	Non-proprietary name	Identified
1	Antipsychotics & Antimanic agents	Vraylar	Cariprazine HCl	**YES**
1	Cardiovascular agents – misc.	Entresto	Sacubitril; Valsartan	No
1	Migraine product	Ajovy	Fremanezumab-vfrm	No
1	Migraine product	Emgality	Galcanezumab-gnlm	No
1	Migraine product	Nurtec	Rimegepant/rimegepant sulfate	No
1	Migraine product	Ubrelvy	Ubrogepant	No
2	Antiasthmatic and bronchodilator	Trelegy	Fluticasone furoate; Umeclidinum bromide; Vilanterol trifenatate	No
2	Anticoagulants	Eliquis	Apixaban	No
2	Anticoagulants	Xarelto	Rivaroxaban	No
2	Dermatological	Cosentyx	Secukinumab	**YES**
2	Digestive Aids	Creon	Pancrelipase (Amylase; Lipase; Protease)	No
3	Antidiabetics	Jardiance	Empagliflozin	No
3	Antidiabetics	Mounjaro	Tirzepatide	No
3	Antidiabetics	Ozempic	Semaglutide	No
3	Antidiabetics	Rybelsus	Semaglutide	No
3	Antidiabetics	Trulicity	Dulaglutide	**YES**
4	Insulin product	Basaglar KwikPen	Insulin Glargine	No
4	Insulin product	Insulin Glargine-yfgn	Insulin Glargine	No
4	Insulin product	Lantus	Insulin Glargine	No
4	Insulin product	Lantus SoloStar	Insulin Glargine	**YES**
4	Insulin product	Semglee	Insulin Glargine	No
4	Insulin product	Toujeo Max SoloStar	Insulin Glargine	No
4	Insulin product	Toujeo SoloStar	Insulin Glargine	No